| Symbol | BBNX |
|---|---|
| Name | BETA BIONICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 11 HUGHES,IRVINE, IRVINE, California, 92618, United States |
| Telephone | 949-427-7785 |
| Fax | — |
| — | |
| Website | https://www.betabionics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001674632 |
| Description | Beta Bionic is a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. Additional info from NASDAQ: |
New Form SCHEDULE 13G - Beta Bionics, Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 0000919574-26-004585 <b>Size:</b> 23 KB
Read moreNew Form 4/A - Beta Bionics, Inc. <b>Filed:</b> 2026-07-02 <b>AccNo:</b> 0002048588-26-000010 <b>Size:</b> 15 KB
Read moreBeta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders
Read moreBeta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Read more📋 Stephen Feider (Officer) plans to sell 5K shares of Beta Bionics, Inc. (at $17.03 each, total $83K) Filed: Jun 26, 2026 | ID: 045940
Read more📋 Stephen Feider (Officer) plans to sell 5K shares of Beta Bionics, Inc. (at $17.05 each, total $87K) Filed: Jun 26, 2026 | ID: 045803
Read moreHopman Mark 🔴 sold 1.3K shares of Beta Bionics, Inc. (BBNX) at $15.01 Transaction Date: Jun 24, 2026 | Filing ID: 000009
Read moreJones Christy 🔴 sold 1.4K shares of Beta Bionics, Inc. (BBNX) at $15.00 Transaction Date: Jun 24, 2026 | Filing ID: 000005
Read more📋 Mark Hopman (Officer) plans to sell 1K shares of Beta Bionics, Inc. (at $14.97 each, total $19K) Filed: Jun 24, 2026 | ID: 045235
Read more📋 CHRISTINA JONES (Director) plans to sell 1K shares of BETA BIONICS, INC. (at $13.67 each, total $19K) Filed: Jun 24, 2026 | ID: 006469
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07011147 | Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery | Na | Type 1 Diabetes (T1D) | Recruiting | 2026-01-16 | 2029-04-01 | ClinicalTrials.gov |
| NCT06449677 | Bionic Pancreas in CFRD | Phase3 | Cystic Fibrosis-related Diabetes | Recruiting | 2024-09-24 | 2027-03-30 | ClinicalTrials.gov |
| NCT04227626 | Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT | Na | Type 1 Diabetes | Withdrawn | 2021-04-01 | 2021-04-01 | ClinicalTrials.gov |
| NCT04200313 | The Insulin-Only Bionic Pancreas Pivotal Trial | Na | Diabetes Mellitus | Completed | 2020-03-31 | 2022-01-14 | ClinicalTrials.gov |
| NCT03840278 | The Bihormonal iLet Bionic Pancreas Feasibility Study | Phase2 | Type 1 Diabetes Mellitus | Completed | 2019-05-15 | 2019-07-03 | ClinicalTrials.gov |
| NCT02971228 | Feasibility Trial Testing the Bionic Pancreas With ZP4207 | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2016-11-01 | 2017-06-07 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Usual Care (UC) | Other | Phase PHASE3 | Cystic Fibrosis-related Diabetes | RECRUITING | NCT06449677 |
| iLet Bionic Pancreas System (BP) | Other | Phase PHASE3 | Cystic Fibrosis-related Diabetes | RECRUITING | NCT06449677 |
| Routine Care | Other | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Bionic Pancreas | Other | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| GlucoSTAT | Other | Approved | Type 1 Diabetes | WITHDRAWN | NCT04227626 |
| Dasiglucagon | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Insulin-only Bionic Pancreas | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Bihormonal iLet Bionic Pancreas | Other | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| iLet-based bionic pancreas | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| iPhone-based bionic pancreas | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Glucagon | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| ZP4207 (dasiglucagon) | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Insulin Lispro | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| BP Guidance Insulin Dosing | Other | Approved | Diabetes Mellitus | COMPLETED | NCT04200313 |
| Usual Care (UC) | Other | Approved | Diabetes Mellitus | COMPLETED | NCT04200313 |
| Bionic Pancreas with Fiasp (BPFiasp) | Other | Approved | Diabetes Mellitus | COMPLETED | NCT04200313 |
| Bionic Pancreas (BP) with Aspart or Lispro | Other | Approved | Diabetes Mellitus | COMPLETED | NCT04200313 |
| Usual Care (UC) | Other | Phase PHASE3 | Cystic Fibrosis-related Diabetes | RECRUITING | NCT06449677 |
| iLet Bionic Pancreas System (BP) | Other | Phase PHASE3 | Cystic Fibrosis-related Diabetes | RECRUITING | NCT06449677 |
| Routine Care | Other | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Bionic Pancreas | Other | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Routine Care | OTHER | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Bionic Pancreas | DEVICE | Approved | Type 1 Diabetes (T1D) | RECRUITING | NCT07011147 |
| Dasiglucagon | DRUG | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Insulin-only Bionic Pancreas | DEVICE | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| Bihormonal iLet Bionic Pancreas | DEVICE | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT03840278 |
| iLet-based bionic pancreas | DEVICE | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| iPhone-based bionic pancreas | DEVICE | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Glucagon | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| ZP4207 (dasiglucagon) | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |
| Insulin Lispro | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT02971228 |